The insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), also known as IMP2. is a member of the conserved RNA-binding protein family that regulates mRNA stability, localization, and translation. It plays a critical role in post-transcriptional gene regulation, particularly in embryogenesis, metabolism, and cancer progression. IGF2BP2 binds to target mRNAs, including IGF2. MYC, and HMGA1. and enhances their expression by shielding them from degradation or promoting translational efficiency. Dysregulation of IGF2BP2 is linked to metabolic disorders like type 2 diabetes and various cancers, where it often acts as an oncoprotein by driving cell proliferation, invasion, and chemoresistance.
Antibodies against IGF2BP2 are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and RNA immunoprecipitation (RIP). Due to structural similarities among IGF2BP family members (IGF2BP1-3), high-specificity antibodies must be rigorously validated to avoid cross-reactivity. Commercial IGF2BP2 antibodies are typically raised against unique epitopes within its N-terminal RNA-binding domains or C-terminal regions. Researchers employ these antibodies to explore IGF2BP2's role in diseases, evaluate its prognostic value in cancer tissues, or investigate its interaction with RNA networks. Recent studies also highlight its potential as a therapeutic target, driving demand for reliable antibodies in preclinical research.